Barclays analyst Andrew Mok lowered the firm’s price target on Surgery Partners (SGRY) to $24 from $25 and keeps an Equal Weight rating on the shares. The company’s Q1 results continued to display resilient demand trends and success in physician recruitment, but these were offset by decelerating pricing and accelerating unit cost trends, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners Reports Q1 Revenue Growth and Reaffirms 2025 Outlook
- Surgery Partners Inc. Reports Strong Growth Amid Challenges
- Positive Outlook for Surgery Partners: Buy Rating Affirmed Amid Margin Expansion and Strategic Growth
- Surgery Partners reports Q1 EPS 4c, consensus 5c
- Surgery Partners reaffirms FY25 revenue view $3.3B-$3.45B, consensus $3.39B